<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161391</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-0046-01</org_study_id>
    <nct_id>NCT04161391</nct_id>
  </id_info>
  <brief_title>Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations</brief_title>
  <official_title>A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turning Point Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turning Point Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and
      preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced
      or metastatic solid tumors harboring RET mutations or alterations. The study consists of two
      portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 2 efficacy
      evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 Dose Escalation: To evaluate the overall safety profile, characterize the PK profiles
      and assess the preliminary efficacy of TPX-0046 in adults subjects with advanced solid tumors
      harboring oncogenic RET fusions or mutations.

      Food Effect Sub-Study: To determine the effect of food on PK of TPX-0046 in adult subjects
      with advanced or metastatic solid tumors harboring oncogenic RET fusions or mutations.

      Phase 2 Efficacy Evaluation: To determine the overall safety and anti-tumor efficacy of
      TPX-0046 in defined cohorts of subjects with advanced/metastatic solid tumors harboring
      oncogenic RET fusions or mutations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0046</measure>
    <time_frame>Within 28 days of the first TPX-0046 dose for each patient</time_frame>
    <description>Evaluate the safety and tolerability of TPX-0046</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the Recommended Phase 2 Dose</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Determine the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of TPX-0046</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the objective response rate (ORR)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine the preliminary efficacy by the ORR in defined cohorts of subjects with advanced/metastatic solid tumors harboring oncogenic RET fusions or mutations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Evaluate the overall safety profile of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration) of TPX-0046</measure>
    <time_frame>Up to 96 hours post-dose</time_frame>
    <description>Evaluate the maximum plasma concentration of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under plasma concentration time curve) of TPX-0046</measure>
    <time_frame>Up to 96 hours post-dose</time_frame>
    <description>Determine the AUC of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration) of TPX-0046 under different food intake conditions</measure>
    <time_frame>Up to 96 hours post-dose</time_frame>
    <description>Determine the effect of food (specifically, a high-fat, high-calorie meal) on the single-dose PK (Cmax) of TPX-0046 at the RP2D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under plasma concentration time curve) of TPX-0046 under different food intake conditions</measure>
    <time_frame>Up to 96 hours post-dose</time_frame>
    <description>Determine the effect of food (specifically, a high-fat, high-calorie meal) on the single-dose PK (AUC) of TPX-0046 at the RP2D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine the preliminary objective response rate (ORR) by Blinded Independent Central Review (BICR) of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine the CBR of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine the TTR of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine the DOR of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine the PFS of TPX-0046</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial tumor response</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine the intracranial tumor response in subjects with measurable brain metastases, as determined by BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Determine efficacy and safety of TPX-0046</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">362</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>RET Gene Mutation</condition>
  <condition>Metastatic Solid Tumor</condition>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TPX-0046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0046.
A food-effect sub-study will be conducted once the RP2D has been determined.
The Phase 2 part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.
Phase 2 Cohorts:
Cohort I (NSCLC + RET fusion, RET TKI Therapy Naive)
Cohort II (NSCLC + RET fusion, RET TKI Therapy Pre-treated)
Cohort III (MTC + RET mutation, RET TKI Therapy Naive)
Cohort IV (MTC + RET mutation, RET TKI Therapy Pre-treated)
Cohort V (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Naive)
Cohort VI (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Pre-Treated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-0046</intervention_name>
    <description>Oral TPX-0046 capsules</description>
    <arm_group_label>TPX-0046</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 (or age ≥ 20 as required by local regulation).

          2. Histological or cytological confirmation of advanced/metastatic solid tumors harboring
             oncogenic RET fusions or mutations, who either have disease progression on, or are
             intolerant to standard therapy; OR are ineligible for standard therapy or for whom no
             standard therapy exists; OR are unlikely to tolerate or derive clinical benefit from
             standard therapy in the opinion of the Investigator OR have declined standard therapy.

          3. ECOG performance status ≤ 1.

          4. Existence of measurable or evaluable disease (according to Response evaluation
             criteria in solid tumors [RECIST v1.1] criteria).

          5. Subjects with asymptomatic primary CNS tumors or brain metastases are eligible for the
             study if they meet protocol specified criteria.

          6. Adequate organ function.

          7. Life expectancy ≥ 12 weeks.

        Exclusion Criteria:

          1. Locally advanced solid tumor that is a candidate for curative treatment through
             radical surgery and/or radiotherapy, or chemotherapy.

          2. Presence or history of any other primary malignancy within 3 years other than a
             history of adequately treated basal or squamous cell carcinoma of the skin, or any
             adequately treated in situ carcinoma.

          3. Major surgery within four weeks of the start of therapy.

          4. Clinically significant cardiovascular disease (either active or within six months
             before enrollment): myocardial infarction, unstable angina, coronary/peripheral artery
             bypass graft, symptomatic congestive heart failure (New York Heart Association
             Classification Class ≥ II), cerebrovascular accident or transient ischemic attack,
             symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac
             dysrhythmias of CTCAE version 5.0 grade ≥ 2.

          5. Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (ECG interval measured from the onset of the
                  QRS complex to the end of the T wave) for heart rate (QTc) &gt; 470 msec obtained
                  from three ECGs, using the screening clinic ECG machine-derived QTc value

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECG (e.g., complete left bundle branch block, third degree heart block,
                  second degree heart block, PR interval &gt; 250 msec)

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, congenital long QT syndrome, family history of long
                  QT syndrome, or any concomitant medication known to prolong the QT interval

          6. Known clinically significant active infections not controlled with systemic treatment
             (bacterial, fungal, viral including HIV positivity).

          7. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut
             syndrome) or other malabsorption syndromes that would impact drug absorption.

          8. Subjects being treated with or anticipating the need for treatment with strong CYP3A4
             inhibitors or inducers.

          9. Subjects with current or anticipated need for drugs that are sensitive CYP2C9
             substrates with narrow therapeutic indices.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Xin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Turning Point Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Xin, MD, PhD</last_name>
    <phone>(858) 276-0005</phone>
    <email>clinical@tptherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCI Health - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Viola Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lyudmila Bazhenova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Doebele, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerald Falchook, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Taofeek Owonikoko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angel Qin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Drilon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vivek Subbiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Medullary Thyroid Cancer</keyword>
  <keyword>MTC</keyword>
  <keyword>RET gene mutation</keyword>
  <keyword>RET gene alteration</keyword>
  <keyword>Advanced non small cell lung cancer</keyword>
  <keyword>Advanced/metastatic disease</keyword>
  <keyword>lung cancer</keyword>
  <keyword>lung adenocarcinoma</keyword>
  <keyword>Metastatic solid tumor</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>RET gene fusion</keyword>
  <keyword>RET inhibitor</keyword>
  <keyword>SRC</keyword>
  <keyword>TPX-0046</keyword>
  <keyword>Thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

